3 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMOCompleted
To demonstrate that Nanocort is safe and effectively reduces the inflammatory signs and symptoms of active GO.
Approved WMOCompleted
The primary objective in the study is to explore the effect of three different amplitude settings (50%…